A review and assessment of potential sources of ethnic differences in drug responsiveness

被引:110
作者
Bjornsson, TD
Wagner, JA
Donahue, SR
Harper, D
Karim, A
Khouri, MS
Murphy, WR
Roman, K
Schneck, D
Sonnichsen, DS
Stalker, DJ
Wise, SD
Dombey, S
Loew, C
机构
[1] Wyeth Res, Clin Pharmacol, Collegeville, PA 19426 USA
[2] Merck & Co Inc, Rahway, NJ 07065 USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Pharmacia, Peapack, NJ USA
[5] Pfizer Inc, Groton, CT 06340 USA
[6] AstraZeneca, Wilmington, DE USA
[7] Lilly, Singapore, Singapore
[8] PhRMA, Washington, DC USA
关键词
ethnic differences; drug development and registration; drug responsiveness; ICH E5 guidelines;
D O I
10.1177/0091270003256065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The International Conference on Harmonization (ICH) E5 guidelines were developed to provide a general framework for evaluating the potential impact of ethnic factors on the acceptability of foreign clinical data, with the underlying objective to facilitate global drug development and registration. It is well recognized that all drugs exhibit significant inter-subject variability in pharmacokinetics and pharmacologic response and that such differences vary considerably among individual drugs and depend on a variety of factors. One such potential factor involves ethnicity. The objective of the present work was to perform an extensive review of the world literature on ethnic differences in drug disposition and responsiveness to determine their general significance in relation to drug development and registration. A few examples of suspected ethnic differences in pharmacokinetics or pharmacodynamics were identified. The available literature, however, was found to be heterologous, including a variety of study designs and research methodologies, and most of the publications were on drugs that were approved a long time ago.
引用
收藏
页码:943 / 967
页数:25
相关论文
共 224 条
[1]  
ABOUAUDA HS, 1998, SAUDI PHARM J, V6, P217
[2]  
ADEDOYIN A, 1994, PHARMACOGENETICS, V4, P27
[3]   Pharmacokinetics of bambuterol during oral administration to asthmatic children [J].
Ahlström, H ;
Alvero, J ;
Alvero, R ;
Espos, R ;
Fajutrao, L ;
Herrera, J ;
Kjellman, B ;
Kubista, J ;
Leviste, C ;
Meyer, P ;
Oldæus, G ;
Siricururat, A ;
Vichyanond, P ;
Wettrell, G ;
Wong, E ;
Laxmyr, L ;
Nyberg, L ;
Olsson, H ;
Weibull, E ;
Rosenborg, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) :299-308
[4]   ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
MACKLIN, B ;
CHALLENOR, VF ;
WALLER, DG ;
GEORGE, CF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :399-403
[5]   The pharmacokinetics and pharmacodynamics of adinazolam: Multi-ethnic comparisons [J].
Ajir, K ;
Smith, M ;
Lin, KM ;
Fleishaker, JC ;
Chambers, JH ;
Anderson, D ;
Nuccio, I ;
Zheng, YP ;
Poland, RE .
PSYCHOPHARMACOLOGY, 1997, 129 (03) :265-270
[6]   EFFECT OF ETHNIC-ORIGIN ON AMPICILLIN BIOAVAILABILITY IN HEALTHY SUDANESE SUBJECTS [J].
ALI, HM ;
HOMEIDA, MMA ;
ELZEIN, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (05) :576-577
[7]  
ALLEN JJ, 1997, POST GRAD MED J S4, V53, P79
[8]  
ANDERSON PJ, 1995, BRIT J CLIN PHARMACO, V39, P361
[9]  
[Anonymous], 1994, Adv Drug Res
[10]  
ARNOLD K, 1970, CLIN PHARMACOL THER, V11, P121